Nearly four decades since the discovery of the association between human leukocyte antigen (HLA) allelic variants and susceptibility in multiple sclerosis (MS), our understanding of the genetic architecture underlying this disease has improved substantially (Box 1). Like other autoimmune diseases, cases of MS cluster in families. Multiple studies have shown for example that monozygotic twins have a higher concordance rate (20%-30%) compared to dizygotic twins (2%-5%), providing strong support for a significant but complex genetic etiology in MS. [1] [2] [3] Interestingly, the concordance rate appears to vary by latitude of birthplace: latitudes with higher MS prevalence also show a higher disease concordance rate in twins, 4 suggesting that gene-environment interactions also play a role in susceptibility. Equally important, siblings of an affected individual are 10-15 times more likely to develop MS than the general population. 1,5 Second-and third-degree relatives, but not spouses, also carry a modest increased risk, 6,7 consistent with genetic factors causing the familial clustering. The genetic component of MS is also reflected in the relative high incidence in some ancestral groups irrespective of geographic location. Finally, MS shows more than expected co-occurrence with other autoimmune diseases affecting different organs, [8] [9] [10] implying commonalities in the genetic factors leading to breakdown in self-tolerance and triggering of autoimmunity. Altogether, the interpretation of the epidemiological data establishes a non-linear relationship between genetic distance from a proband and disease lifetime risk, firmly clustering MS with the so-called complex genetic disorders. These are relatively common diseases characterized by moderate heritability, polygenicity, and multifaceted geneenvironment interactions. 11, 12 The polygenic model of MS heritability offered the rationale and drive for assembling well-powered DNA sample collections for agnostic genome-wide association studies (GWAS). Enabled by steady technological improvements and a new generation of more informative and efficient DNA microarrays, GWAS and other large-scale but targeted genomic screens in populations of European descent have identified, so far, 234 independent regions across the genome associated with susceptibility, including 32 independent allelic and locus effects within the extended major histocompatibility complex (MHC) region in the short arm of chromosome 6, and one in chromosome X. [13] [14] [15] [16] [17] The notable overlap between MS-associated DNA variants and those associated with other autoimmune diseases is one of the most interesting observations to emerge from GWAS, 18 but the fact that some variants might be associated with two traits and yet have opposite effects illustrates the
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Building on this genetic atlas, follow-up experimental observations have begun to refine our understanding of disease pathogenesis by suggesting mechanistic insights into the functional roles of the identified allelic variants. [19] [20] [21] Significantly, these studies have confirmed the role of adaptive and innate immune cells and pathways steering the risk of developing MS. 22 The results also suggest functional responses of brain-resident cells such as microglia and astrocytes affecting susceptibility. For most loci, however, the specific DNA variation causative of the association statistical signal and the mechanism linking susceptibility with brain inflammation and autoimmunity remain unknown. Linkage disequilibrium is an inherent feature of genomic architecture that limits the resolution of GWAS data. As a result, the implicated regions tagged by the associated single-nucleotide polymorphisms (SNPs) can be large and include several potential candidate genes. Furthermore, most of the top associated SNPs fall in non-coding segments of the genomes, preventing a straightforward modeling of the association results.
The strongest disease association signal genome-wide maps within the 4 Mb major histocompatibility locus (MHC) region in chromosome 6p21. 15, 23 The influence of this region in MS susceptibility was first recognized 40 years ago based on observed higher frequencies of specific serological specificities defining HLA epitope binding sites in patients compared to controls. Since then, the association, more specifically with the HLA-DRB1 gene, has been consistently observed across all populations studied. In Europeans, the HLA-DRB1*15:01 allelic variant carries an average odds risk (OR) of 3.08 with a distinct dose response in risk according to 0, 1, or 2 allele copies the individual carries. Interestingly, in African Americans, the OR values for HLA-DRB1*15:01 decline to the 1.8 range. Genetic heterogeneity in the form of hierarchical HLA-DRB1 allelic lineages and copy number effects have been described (but not fully understood). In addition to the HLA-DRB1 signal, complex cis and trans effects can be found across the locus, including protective effects mapped to the telomeric class I region. 24, 25 Furthermore, besides the classical HLA loci, the MHC region is also home to over 150 genes, about half having roles in the immune response, and robust non-HLA genetic associations have been documented and reported. 24, 26 Multiple theories have been proposed to explain the HLA association with risk, including the specificity of peptide-(auto)antigen binding, differential levels of expression, and perturbations in central tolerance. However, the exact mechanism(s) by which HLAcoded products contributes to MS susceptibility remains unknown. Thus, despite a remarkable body of epidemiological, immunological, and molecular data, additional high-resolution studies are needed to generate unifying models that reliably account for the role of the whole MHC and HLA genes in particular in disease pathogenesis.
A decade long effort of genomic screens provided unambiguous statistical evidence for the association of over 200 non-MHC loci with disease susceptibility. The mapping of additional risk variants is likely to follow rapidly utilizing next-generation genotyping and sequencing techniques. Unpublished meta-analysis of GWAS-derived data shows over 400 additional loci that, without attaining genome-wide statistical significance, are good candidates to be involved in risk (i.e. high probability of reaching statistical confirmation with adequately large sample sets). Although there is a strong rationale for identifying all common genetic variants associated with disease risk, it is not inconceivable, however, that the potential for the discovery of additive risk variance extractable from genome-wide screens will be eventually exhausted without accounting for all determinants of risk. Similar to other complex genetic diseases, additional explanations for the missing heritability in MS have been proposed, including gene by gene and gene by environment interactions, unidentified regulators of allelic expression, rare and penetrant semi-private variants, population and/or disease heterogeneity, underpowered analysis of sex chromosomes, and hidden epigenetic effects. Epigenome-wide studies represent an attractive approach to identify heritable regulatory processes and disease-modifying responses to environmental effects, 27, 28 and genome-wide analyses of epigenetic modifications in MS, primarily DNA methylation, begin to emerge. 29, 30 In addition to the effort to understand risk heritability, there are other significant questions that remain to be addressed to make the most of genetic research in MS, including the need to describe the relationship between genotype and phenotype and identify markers of disease progression. Modest familial effects on the clinical course of MS suggest that in addition to susceptibility, genetic variance also plays a role in disease trajectory. Significantly, the main susceptibility biomarker HLA-DRB1*15:01 has been associated with phenotypic markers of disease severity. [31] [32] [33] [34] In the University of California, San Francisco (UCSF) cohort, DRB1*15:01 is associated with atrophy of subcortical gray matter fraction in female relapsingonset patients (p = 2.3e-04), whereas the protective allele HLA-B*44:02 is negatively associated with subcortical gray atrophy (p = 0.036). 35 In addition, we observed a distinct association of the HLA-A*24:02-B*07:02-DRB1*15:01 extended haplotype with shrinkage of subcortical gray matter fraction (p = 5.1e-03). Surprisingly, the HLA-A*X-HLA-B*X-DRB1*15:01 haplotype, which included close to half of the HLA-DRB1*15:01 positive dataset, did not have any correlation with the phenotype, suggesting strongly that genetic variants within the MHC other than HLA-DRB1 influence disease trajectory in MS. One caveat of published genotype-phenotype studies in MS is that most examine cross-sectional phenotypic endpoints. It is possible that genes involved in the distinct MS phenotypes are missed if they exert their effects after the time of analysis. Longitudinal studies, carefully tracking as early as possible changes in quantitative metrics of disease severity over time, may prove to be more efficient in identifying genes involved in MS progression and clinical phenotypes.
Ultimately, the goal of genetic studies is to achieve a more refined representation of genes, pathways, and networks involved in disease pathogenesis, and leverage this information to discover novel targets for therapy, prevention, and repair. The next phase of the work will focus on identifying the causative variants responsible for association signals at every locus and defining their functional roles, alone or in combinations, on the initiation and the clinical expression of the disease (Box 2). These aims are achievable through the convergence and integration of genetics, functional genomics, and next-generation neuroimaging and informatics.
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